Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results
Cancer
 

Click here to go back to your search results.

Prostate Cancer treatment details. Biologic therapy. Massachusetts General Hospital Cancer Center, Boston, MA, United States



Survival: 43.9 months
   
Toxicity Grade: 5
   
Treatments: Biologic therapy
   
Drugs:
Country: United States
   
City/State/Province: Boston, MA
   
Hospital: Massachusetts General Hospital Cancer Center
   
Journal: Link
   
Date: 1/2012

Description:
Patients:
This phase 3 study involved 716 men with castration-resistant prostate cancer. The median patient age was 74 years.

Treatment:
Patients were treated with the biologic therapy agent denosumab, which is a monoclonal antibody that inactivates a protein called RANKL and subsequently works to prevent bone metastases commonly associated with prostate cancer.

Toxicities:
Treatment-related deaths were reported, but specific causes were not given. Severe anemia, urinary tract infection, and loss of bone density were reported.

Results:
The reported median overall survival was 43.9 months.

Support:
This study was supported by Amgen, makers of denosumab.

Correspondence: Dr. Matthew R Smith; email: smith.matthew@mgh.harvard.edu

E-mail to a Friend Email Physician More Information